Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Buy" from Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) has received an average rating of "Buy" from the six analysts that are covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $30.83.

A number of analysts have issued reports on TYRA shares. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Tuesday. Piper Sandler initiated coverage on Tyra Biosciences in a research note on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price target for the company. Finally, Wedbush restated an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th.

Tyra Biosciences Price Performance

Shares of Tyra Biosciences stock traded down $0.06 during trading hours on Tuesday, hitting $10.00. 209,584 shares of the company's stock traded hands, compared to its average volume of 286,105. The stock has a market capitalization of $530.63 million, a price-to-earnings ratio of -6.13 and a beta of 1.07. Tyra Biosciences has a 12-month low of $6.42 and a 12-month high of $29.60. The company has a fifty day simple moving average of $9.87 and a 200-day simple moving average of $11.41.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. On average, analysts forecast that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insider Activity at Tyra Biosciences

In related news, Director Gilla Kaplan sold 30,000 shares of the business's stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $10.31, for a total transaction of $309,300.00. Following the sale, the director directly owned 59,623 shares in the company, valued at approximately $614,713.13. The trade was a 33.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 61,392 shares of company stock valued at $628,358 over the last three months. 15.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS purchased a new stake in shares of Tyra Biosciences in the fourth quarter worth about $31,000. US Bancorp DE bought a new stake in Tyra Biosciences during the 4th quarter worth approximately $50,000. BNP Paribas Financial Markets purchased a new stake in Tyra Biosciences in the 4th quarter worth approximately $60,000. Aquatic Capital Management LLC bought a new position in Tyra Biosciences in the 4th quarter valued at $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Tyra Biosciences during the 1st quarter valued at $84,000. Institutional investors own 84.14% of the company's stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.